PDLIM7通过稳定黏着斑激酶蛋白促进甲状腺乳头状癌肿瘤转移
该研究利用80例甲状腺乳头状癌(PTC)患者队列及癌症基因组图谱(TCGA)中512例PTC样本分析PDLIM7表达与预后,并通过体外功能实验和异种移植小鼠模型探讨其作用机制。结果显示PDLIM7蛋白在PTC组织和细胞中常上调,与晚期临床病理特征相关;敲低PDLIM7可抑制PTC细胞增殖、迁移、侵袭及TPC-1异种移植瘤生长和转移。PDLIM7与FAK及ITGAV共定位,敲低PDLIM7导致黏着斑解聚和FAK蛋白酶体依赖性降解。
要点
- PDLIM7蛋白在PTC组织和细胞中常上调,高表达与晚期临床病理特征相关。
- 敲低PDLIM7可抑制PTC细胞体外增殖、迁移、侵袭及体内TPC-1异种移植瘤生长和转移。
- PDLIM7与FAK及ITGAV共定位,敲低PDLIM7导致黏着斑解聚和FAK蛋白酶体依赖性降解。
核心结论
- PDLIM7在PTC中作为癌蛋白发挥促进转移的作用。
- 作者提出一种新机制:PDLIM7保护FAK蛋白免于蛋白酶体依赖性降解。
研究设计与样本
- 研究纳入桂林医学院第二附属医院80例PTC患者队列,以及癌症基因组图谱甲状腺癌数据库中512例PTC样本,分析PDLIM7表达及其与预后的关联。
- 采用Kaplan-Meier曲线评估生存数据,并考虑年龄、性别、肿瘤大小、多灶性、甲状腺外侵犯、淋巴结转移、桥本甲状腺炎、远处转移和TNM分期等临床病理特征。
- 在体外功能实验和异种移植小鼠模型中评估PDLIM7在PTC细胞系中的作用。
- 采用免疫荧光和免疫沉淀法检测PDLIM7与FAK及ITGAV的共定位,通过Western blotting和免疫组织化学检测细胞和组织活检中的蛋白表达水平。
主要发现
- PDLIM7蛋白在PTC组织和细胞中频繁上调,PDLIM7过表达与晚期临床病理特征相关。
- 在体外,敲低PDLIM7有效抑制PTC细胞系的细胞增殖、迁移和侵袭。
- 在体内,敲低PDLIM7阻碍TPC-1异种移植瘤的生长和转移。
- PDLIM7与FAK及黏着斑分子ITGAV共定位,敲低PDLIM7导致PTC细胞系中黏着斑解聚和FAK的蛋白酶体依赖性降解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: As an actin cytoskeleton interactor, PDZ (postsynaptic density 65-discs large-zonula occludens 1) and LIM (abnormal cell lineage 11-isket 1-mechanosensory abnormal 3) domain protein 7 (PDLIM7) was supposed to play an essential role modulating cytoskeleton. Focal adhesions (FAs), which are located at the cytomembrane terminus of actin cytoskeleton, function as a force sensor and can transform the mechanical signal to a biochemical signal. Focal adhesion kinase (FAK) localizes to and regulates signal transduction in FAs, which play an essential role in cell polarity, migration, and invasion. However, whether PDLIM7 is involved in FAs-associated signal transduction and its role in tumor invasion and metastasis remains largely unknown. Methods: A cohort of 80 patients with papillary thyroid carcinoma (PTC) at The Second Affiliated Hospital of Guilin Medical University, as well as 512 PTC samples from The Cancer Genome Atlas thyroid cancer database was utilized to analyze the expression of PDLIM7 and its association with prognosis. Survival data were assessed using Kaplan-Meier curves, whereas clinicopathological characteristics such as age, sex, tumor size, multilocality, extrathyroidal extension, lymph metastases, Hashimoto's thyroiditis, distant metastasis, and TNM stage were considered. Functional assays were performed in vitro and in a xenograft mouse model to assess the role of PDLIM7 in PTC cell lines. The colocalization of PDLIM7 with FAK and integrin alpha V (ITGAV) was determined using immunofluorescence assay and immunoprecipitation assay. Protein expression levels in cell and tissue biopsies were measured through Western blotting and immunohistochemistry. Results: (1) The PDLIM7 protein frequently upregulated in both PTC tissues and cells, and overexpression of PDLIM7 is associated with advanced clinicopathological characteristics. (2) Knockdown of PDLIM7 effectively inhibits cell proliferation, migration, and invasion in PTC cell lines in vitro. (3) Knockdown of PDLIM7 hinders the growth and metastasis of TPC-1 xenografts in vivo. (4) PDLIM7 demonstrates colocalization with both FAK and the FA molecule ITGAV and the knockdown of PDLIM7 resulted in disassembly of FAs and proteosome-dependent degradation of FAK in PTC cell lines. Conclusions: PDLIM7 function as an oncoprotein in PTC to promote metastasis, and a novel underlying mechanism is proposed that PDLIM7 keeps FAK protein from proteosome-dependent degradation.
引用
- Yang F, Yang M, Liu Y, et al. PDLIM7 Promotes Tumor Metastasis in Papillary Thyroid Carcinoma via Stabilizing Focal Adhesion Kinase Protein. Thyroid. 2024. PMID: 38243825. doi:10.1089/thy.2023.0497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。